These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39327962)

  • 21. Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study.
    Yang X; Bai Y; Shi M; Zhang W; Niu J; Wu C; Zhang L; Xu Z; Liu X; Chen Y; Sun K
    Cancer Manag Res; 2020; 12():1293-1301. PubMed ID: 32110103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
    Pfirrmann M; Clark RE; Prejzner W; Lauseker M; Baccarani M; Saussele S; Guilhot F; Heibl S; Hehlmann R; Faber E; Turkina A; Ossenkoppele G; Höglund M; Zaritskey A; Griskevicius L; Olsson-Strömberg U; Everaus H; Koskenvesa P; Labar B; Sacha T; Zackova D; Cervantes F; Colita A; Zupan I; Bogdanovic A; Castagnetti F; Guilhot J; Hasford J; Hochhaus A; Hoffmann VS
    Leukemia; 2020 Aug; 34(8):2138-2149. PubMed ID: 32601376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase.
    Alonso-Dominguez JM; Grinfeld J; Alikian M; Marin D; Reid A; Daghistani M; Hedgley C; O'Brien S; Clark RE; Apperley J; Foroni L; Gerrard G
    Am J Hematol; 2015 Jan; 90(1):20-6. PubMed ID: 25250944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia: A single-center experience in China.
    Deng M; Guan X; Wen X; Xiao J; An X; Yu J
    Medicine (Baltimore); 2020 Feb; 99(7):e19150. PubMed ID: 32049841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
    Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
    [No Abstract]   [Full Text] [Related]  

  • 26. [Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients].
    Creutzig U; Ritter J; Zimmermann M; Klingebiel T
    Klin Padiatr; 1996; 208(4):236-41. PubMed ID: 8926689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy.
    Zhang XS; Gale RP; Zhang MJ; Huang XJ; Jiang Q
    Leukemia; 2022 May; 36(5):1336-1342. PubMed ID: 35194158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country.
    Bourlon C; Hernandez-Mata C; Vargas-Serafín C; Bourlon MT; Tuna-Aguilar E; Aguayo A
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):453-9. PubMed ID: 27259590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term survival in chronic myeloid leukemia: frequency and fundamental characteristics in a series of 100 patients].
    Cervantes F; Bosch F; Terol MJ; Pereira A; Rozman C
    Sangre (Barc); 1993 Apr; 38(2):93-6. PubMed ID: 8516734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
    Radich JP; Hochhaus A; Masszi T; Hellmann A; Stentoft J; Casares MTG; García-Gutiérrez JV; Conneally E; le Coutre PD; Gattermann N; Martino B; Saussele S; Giles FJ; Ross DM; Aimone P; Li S; Titorenko K; Saglio G
    Leukemia; 2021 May; 35(5):1344-1355. PubMed ID: 33707652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Lee SE; Choi SY; Kim SH; Song HY; Yoo HL; Lee MY; Kang KH; Hwang HJ; Jang EJ; Kim DW
    Korean J Intern Med; 2017 Jan; 32(1):125-136. PubMed ID: 27334764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia].
    Huang J; Zhao X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 41(8):809-14. PubMed ID: 27600007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
    Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H
    Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asymptomatic chronic-phase chronic myeloid leukemia BCR-ABL. (+) without splenomegaly: A case report.
    Rajabto W; Angkasa YK
    Niger J Clin Pract; 2022 Mar; 25(3):373-375. PubMed ID: 35295063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study.
    Mao XL; Xi YM; Li ZJ; Jia MF; Li M; Wang LN; Zhao L; Zhang H
    Medicine (Baltimore); 2021 Mar; 100(10):e24003. PubMed ID: 33725811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.
    Brunner AM; Campigotto F; Sadrzadeh H; Drapkin BJ; Chen YB; Neuberg DS; Fathi AT
    Cancer; 2013 Jul; 119(14):2620-9. PubMed ID: 23625575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
    Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The prognostic value of early BCR-ABL transcripts level in 251 patients with chronic myeloid leukemia after treatment with imatinib].
    Bao X; Qiu H; Chen S; Ma X; Tang X; Fu C; Sun A; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):553-8. PubMed ID: 26304076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population.
    Yahng SA; Jang EJ; Choi SY; Lee SE; Kim SH; Kim DW
    Int J Hematol; 2014 Aug; 100(2):132-40. PubMed ID: 24879034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.